Business Wire

AZ-EDGIO

22.2.2024 14:01:35 CET | Business Wire | Press release

Share
Web Application Attacks Intensify in Fourth Quarter of 2023, According to New Edgio Quarterly Attack Trends Report

Edgio (NASDAQ: EGIO), the platform of choice for speed, security, and simplicity at the edge, found that web application attacks continued to increase and evolve in the fourth quarter of 2023, as reported in its new Edgio Quarterly Attack Trends Report in which the company analyzed 5.2 billion attack requests. Edgio found that the most prevalent attack mitigated was path traversal. A successful path traversal attack allows a threat actor to access files on a web server, and has surpassed the prior #1 threat, SQL injection, a common attack vector that often uses malicious SQL statements to attempt to exfiltrate sensitive data from databases behind applications.

Edgio’s report explains how path traversal attacks can lead to deep system intrusions posing a significant threat to an organization’s infrastructure and the confidentiality, integrity, and availability of data delivered over the Internet. These attacks can result in unauthorized access to content, the loss of personally identifiable information (PII), the dissemination of private/copyrighted information, or even remote code execution. Unmitigated attacks can lead to even more serious consequences, such as the deployment of ransomware or other malicious software.

“As one of the leading edge-computing providers, Edgio has unparalleled visibility into the threats facing web applications today,” said Tom Gorup, Vice President of Security for Edgio. “We are assembling our knowledge and expertise into a quarterly read-out to enable enterprises to better protect their web infrastructure and applications. As more businesses become dependent on their digital assets, it’s critical this knowledge is shared to build a safer Internet.”

The report looked at malicious requests and the different types of blocking, categorizing protection into three categories: access control rules, managed rulesets, and custom signatures. Of those that were focused on access controls, over 76% of mitigated requests were based on IP, user-agent, and country matches, highlighting just how much bad traffic can be eliminated with basic blocklisting tactics. With managed rulesets, Edgio saw a wide range of threat types blocked, with path traversal, SQL injection and cross-site scripting (XSS) attacks leading the way when it comes to OWASP attacks.

In addition, Edgio was able to review web application firewall (WAF) request denials by country of origin, while noting that attackers often leverage local resources to launch attacks in order to evade geofencing tactics. This could explain why attacks coordinated from advanced threat actors in more prominent countries did not crack Edgio’s Top 10 for the quarter.

Top countries by malicious request origin, making up nearly 62% of all requests denied, include:

  • United States – 26.3%
  • France – 17.4%
  • Germany – 9.4%
  • Russia – 8.8%

Edgio found that WAF customers used access control features to allow or deny specific request methods, using their knowledge of their own applications to inform their security controls and lower risk. The report indicates that attackers frequently leverage request methods like HEAD that return app and infrastructure information that can be used by the attacker for reconnaissance purposes and to craft a malicious payload.

Based on deep parsing of attack payloads, Edgio found that 98% of all malicious payloads fell into JavaScript Object Notation (JSON) and URL encoded form categories (used for storing and transporting data) but cautioned security teams to remain vigilant as attackers evolve in their selection of payload content types.

Best practices for digital asset protection: proactively stop threats against websites and applications

Based on its findings, Edgio recommends the following methods to best protect digital assets, including websites and applications:

  • Ensure your WAF provides a layered defense to protect organizations against the known bad, application-specific, and emerging threats. A complete solution will show a distribution of enforcement across access control rules, managed rulesets, and custom signatures.
  • Blocklists are still an effective and low-cost part of a layered security approach to safeguard Internet-facing assets. Organizations should also take advantage of threat intelligence feeds to further harden their security posture against known bad actors.
  • While managed rules are often maintained and updated by your WAF provider, it is not advisable to use a ‘set it and forget’ approach. As an application evolves and new functionalities are developed, policy reviews and analysis of managed ruleset enforcement is recommended. It is best to ensure rules are closely aligned with business application needs.
  • Organizations should take the time to understand where they are doing business and where they aren’t allowed to do business. Block the countries or sub-regions that bring no value to a brand to reduce their attack surface. Blocking embargoed countries is a great starting point, but don’t rely on this approach as a catch all for bad actors.
  • Know the application and use this knowledge to inform security solutions, like a WAF, to limit the application request methods or content types based on application needs.

To obtain a full copy of the report, click here.

About Edgio

Edgio (NASDAQCM: EGIO) helps companies deliver online experiences and content faster, safer and with more control. Our developer-friendly, globally scaled edge network, combined with our fully integrated application and media solutions, provides a single platform for delivering high-performing, secure web properties and streaming content. Companies can deliver content quicker and more securely through this fully integrated platform and end-to-end edge services, boosting overall revenue and business value. To learn more, visit edg.io and follow us on Twitter, LinkedIn and Facebook.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240222674952/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye